Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 64.11% | 68.81% | 66.00% | 57.12% | -362.87% |
| Total Depreciation and Amortization | 5.95% | -6.85% | -14.86% | -22.15% | 2.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.27% | -93.45% | -91.42% | -86.30% | 1,391.31% |
| Change in Net Operating Assets | -22.09% | 12.79% | 53.91% | 214.40% | 154.28% |
| Cash from Operations | -19.10% | 65.42% | 57.83% | 73.58% | 79.39% |
| Capital Expenditure | -- | -- | -- | -- | 93.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 4,639.33% |
| Total Debt Issued | 184.86% | 150.70% | 267.61% | 680.08% | 144.95% |
| Total Debt Repaid | -623.31% | -486.10% | -13.36% | -12.85% | 38.58% |
| Issuance of Common Stock | -90.57% | -95.90% | -99.55% | -88.01% | -83.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 101.85% | 101.85% | -- | -- | -200.78% |
| Cash from Financing | 195.80% | 166.74% | 195.45% | -32.48% | -129.66% |
| Foreign Exchange rate Adjustments | 100.00% | 100.47% | 100.00% | 95.17% | -146.62% |
| Miscellaneous Cash Flow Adjustments | -100.00% | -100.00% | -100.00% | -100.00% | 462.77% |
| Net Change in Cash | 248.87% | 134.21% | 104.87% | 73.68% | 5.47% |